Raleigh Capital Management Inc. purchased a new position in Sanofi (NASDAQ:SNY – Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 23,302 shares of the company’s stock, valued at approximately $1,268,000.
Other large investors have also recently made changes to their positions in the company. Putnam Investments LLC increased its position in Sanofi by 14.2% during the 1st quarter. Putnam Investments LLC now owns 922,549 shares of the company’s stock valued at $50,205,000 after buying an additional 114,775 shares in the last quarter. Ameriprise Financial Inc. increased its position in Sanofi by 20.7% during the 1st quarter. Ameriprise Financial Inc. now owns 359,095 shares of the company’s stock valued at $19,598,000 after buying an additional 61,696 shares in the last quarter. Westover Capital Advisors LLC increased its position in Sanofi by 39.3% during the 1st quarter. Westover Capital Advisors LLC now owns 10,937 shares of the company’s stock valued at $595,000 after buying an additional 3,087 shares in the last quarter. Harvest Portfolios Group Inc. increased its position in Sanofi by 298.1% during the 1st quarter. Harvest Portfolios Group Inc. now owns 41,800 shares of the company’s stock valued at $2,275,000 after buying an additional 31,300 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. increased its position in Sanofi by 10.9% during the 1st quarter. B. Riley Wealth Advisors Inc. now owns 17,115 shares of the company’s stock valued at $931,000 after buying an additional 1,685 shares in the last quarter. 10.06% of the stock is owned by institutional investors.
Sanofi Stock Down 0.7 %
Shares of SNY stock opened at $54.27 on Wednesday. The stock’s 50-day simple moving average is $53.10 and its 200-day simple moving average is $53.63. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.81 and a current ratio of 1.21. The firm has a market capitalization of $137.02 billion, a PE ratio of 18.61, a P/E/G ratio of 1.58 and a beta of 0.57. Sanofi has a fifty-two week low of $36.91 and a fifty-two week high of $57.82.
Wall Street Analysts Forecast Growth
SNY has been the topic of several recent analyst reports. HSBC initiated coverage on Sanofi in a research report on Friday, July 14th. They set a “buy” rating on the stock. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 29th. Finally, Berenberg Bank raised Sanofi from a “hold” rating to a “buy” rating in a report on Tuesday, September 5th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $72.50.
Sanofi Company Profile
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
- Five stocks we like better than Sanofi
- Best Restaurant Stocks to Invest in Now
- 3 Reasons Dollar General Shares Belong in the Shopping Cart
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Shell’s 4.12% Dividend Yield: An Attractive Feature for Investors
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Apple Shares Stumble Into The Buy Zone
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.